Send to:

Choose Destination
See comment in PubMed Commons below
Dement Geriatr Cogn Dis Extra. 2013 May 1;3(1):143-7. doi: 10.1159/000350029. Print 2013 Jan.

The Effect of Solifenacin on Cognitive Function following Stroke.

Author information

  • 1Department of Physical Medicine and Rehabilitation, Dongguk University Ilsan Hospital, Goyang-si, Republic of Korea.



Our aim was to investigate the effect of solifenacin (an anticholinergic) on cognitive function after stroke.


We retrospectively reviewed 66 stroke cases who were prescribed solifenacin for more than 2 months. A control group was generated matching the patients both for sex and age. The interval changes in the Mini-Mental State Examination (MMSE) score and Clinical Dementia Rating Sum of Boxes (CDR-SB) score after solifenacin administration were compared to those of the control group.


The baseline MMSE score of the control group was 15.9 ± 9.2 and that of the solifenacin group was 14.3 ± 7.8. After using solifenacin for an average of 76.9 days, there was a change in the MMSE score of 1.9 ± 5.2. During similar periods, there was a change in the MMSE score of 2.9 ± 3.7 in the control group (not using solifenacin). However, there was no significant difference between the two groups. Similarly, there was no significant difference in the CDR-SB score between the two groups.


Solifenacin treatment did not affect the short-term cognitive performance in stroke patients. This information might be useful when prescribing anticholinergics to stroke patients.


Anticholinergics; Cognitive symptoms; Muscarinic receptors; Solifenacin; Stroke

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Write to the Help Desk